- Home
- MCRB vs BFIN Comparison
MCRB vs BFIN Comparison
Compare MCRB & BFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- BFIN
- Stock Information
- Founded
- MCRB 2010
- BFIN 1924
- Country
- MCRB United States
- BFIN United States
- Employees
- MCRB N/A
- BFIN N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- BFIN Savings Institutions
- Sector
- MCRB Health Care
- BFIN Finance
- Exchange
- MCRB Nasdaq
- BFIN Nasdaq
- Market Cap
- MCRB 156.3M
- BFIN 156.3M
- IPO Year
- MCRB 2015
- BFIN N/A
- Fundamental
- Price
- MCRB $0.84
- BFIN $12.16
- Analyst Decision
- MCRB Buy
- BFIN
- Analyst Count
- MCRB 4
- BFIN 0
- Target Price
- MCRB $5.63
- BFIN N/A
- AVG Volume (30 Days)
- MCRB 2.4M
- BFIN 17.7K
- Earning Date
- MCRB 11-13-2024
- BFIN 01-29-2025
- Dividend Yield
- MCRB N/A
- BFIN 3.25%
- EPS Growth
- MCRB N/A
- BFIN N/A
- EPS
- MCRB N/A
- BFIN 0.63
- Revenue
- MCRB $126,325,000.00
- BFIN $54,348,000.00
- Revenue This Year
- MCRB N/A
- BFIN N/A
- Revenue Next Year
- MCRB N/A
- BFIN $0.85
- P/E Ratio
- MCRB N/A
- BFIN $19.41
- Revenue Growth
- MCRB 12856.41
- BFIN N/A
- 52 Week Low
- MCRB $0.54
- BFIN $9.60
- 52 Week High
- MCRB $2.05
- BFIN $13.97
- Technical
- Relative Strength Index (RSI)
- MCRB 47.60
- BFIN 40.55
- Support Level
- MCRB $0.80
- BFIN $12.14
- Resistance Level
- MCRB $1.00
- BFIN $12.74
- Average True Range (ATR)
- MCRB 0.06
- BFIN 0.41
- MACD
- MCRB -0.01
- BFIN -0.08
- Stochastic Oscillator
- MCRB 20.46
- BFIN 7.63
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About BFIN BankFinancial Corporation
BankFinancial Corp is a national bank principally engaged in the business of commercial, family and personal banking. It offers customers a broad range of loan, deposit, trust and other financial products and services. The Bank offers customers a broad range of loan, deposit, trust and other financial products and services through all full-service banking offices located in Cook, DuPage, Lake and Will Counties, Illinois and through Internet Branch.